Ignite Creation Date:
2024-05-06 @ 7:31 PM
Last Modification Date:
2024-10-26 @ 3:09 PM
Study NCT ID:
NCT06048666
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-09-21
First Post:
2023-09-16
Brief Title:
Platelet Rich Plasma on Ovarian Reserve Parameters and Intra Cytoplasmic Sperm Injection Outcomes in Patients With Diminished Ovarian Reserve
Sponsor:
Beni-Suef University
Organization:
Beni-Suef University
Study Overview
Official Title:
Effect of Intra-ovarian Injection of Autologous Platelet Rich Plasma on Ovarian Reserve Parameters and Intra Cytoplasmic Sperm Injection Outcomes in Patients With Diminished Ovarian Reserve
Status:
NOT_YET_RECRUITING
Status Verified Date:
2023-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of this study is to evaluate the efficacy of intra ovarian injection of autologous platelet rich plasma on ovarian reserve parameters and ICSI outcomes in poor ovarian reserve
Detailed Description:
fifty_six infertile women suffering from poor ovarian reserve following up at IVF Unit of Beni_suef University hospital and they fulfilled inclusion and exclusion criteria they will be classlfied into two groups Group A study group involve 28 patient will be injected intra ovarian by platelet rich plasma Group B control group involve 28 patient will not be injected intra ovarian by platelet rich Plasma
The researcher will introduce himself to all participants included in this study and requested that they participate after explaining the purpose of the study All participants will be given detailed information about the studys goal and predicted advantages All participants will give their informed verbal agreement and the data will be kept confidential All patients will be subjected to
Complete history was taken with special emphasis on
Personal pastfamilysurgical history Menstrual historyObstetric history
Clinical examination
Physical examination included General examination Weight Height BMI Abdominal examination Local Pelvic examination
Ultrasound examination
The women will be in lithotomy position with an empty bladder On day 2 of the menstrual cycle or withdrawal bleed a sterile vaginal speculum has been introduced and a TV ultrasonography probe 70-MH endo-vaginal probe has been placed in the vagina roughly 1 cm away from the cervix to evaluate the volume of the ovary and antral follicle counts AFC
Investigations
General CBC urinalysis Random blood sugar when needed Specific Hormonal profile in all patients of the study the following were obtained prior to the procedure Anti-Mullerian hormone AMH FSH Estradiol
PRP preparation and time of injection On the day of PRP infusion within 10 days after completion of menstrual bleeding we will take 20 cc of venous blood from each participant of group A to prepare PRP The blood will be transferred to a tube containing sodium citrate and centrifuged at 800 RPM for 15 min and 2000 RPM for 5 min in two stages respectively Then by discarding part of the plasma PRP will be prepared with a final concentration of one million platelets per microliter The PRP will be injected into the ovary under spinal anesthesia and a transvaginal ultrasound guide
Patien assessment and Follow up patients injected with PRP will be managed expectantly for 6 weeks to allow spontaneous pregnancy at the beginning of second menstrual cycle AMH FSH AFC will be reassessed
3months after the PRP injection all women considered poor responders 2groupswill undergo assisted reproductive therapy with antagonist protocol followed by a dose of 450 units of FSH Gonal F CinnaGen Iran Six days after gonadotropin therapy vaginal ultrasound will be performed to measure follicle diameter Once the follicular size is 12 mm the GnRH antagonist Cetrorelix Merck-Serono Germany will begin and gonadotropin continued When at least two dominant follicles reach the diameter of 18 mm on ultrasound ovulation will be stimulated using 10000 units of HCG and oocyte retrieval will be performed under general anesthesia 34 to 36 h after the HCG injection and the two groups will be compared in terms of the outcomes such as duration of stimulation dosage of gonadotrophine serum of estradiol level on the triggering day number and quality of oocytes and embryons and clinical pregnancy
The researcher will introduce himself to all participants included in this study and requested that they participate after explaining the purpose of the study All participants will be given detailed information about the studys goal and predicted advantages All participants will give their informed verbal agreement and the data will be kept confidential All patients will be subjected to
Complete history was taken with special emphasis on
Personal pastfamilysurgical history Menstrual historyObstetric history
Clinical examination
Physical examination included General examination Weight Height BMI Abdominal examination Local Pelvic examination
Ultrasound examination
The women will be in lithotomy position with an empty bladder On day 2 of the menstrual cycle or withdrawal bleed a sterile vaginal speculum has been introduced and a TV ultrasonography probe 70-MH endo-vaginal probe has been placed in the vagina roughly 1 cm away from the cervix to evaluate the volume of the ovary and antral follicle counts AFC
Investigations
General CBC urinalysis Random blood sugar when needed Specific Hormonal profile in all patients of the study the following were obtained prior to the procedure Anti-Mullerian hormone AMH FSH Estradiol
PRP preparation and time of injection On the day of PRP infusion within 10 days after completion of menstrual bleeding we will take 20 cc of venous blood from each participant of group A to prepare PRP The blood will be transferred to a tube containing sodium citrate and centrifuged at 800 RPM for 15 min and 2000 RPM for 5 min in two stages respectively Then by discarding part of the plasma PRP will be prepared with a final concentration of one million platelets per microliter The PRP will be injected into the ovary under spinal anesthesia and a transvaginal ultrasound guide
Patien assessment and Follow up patients injected with PRP will be managed expectantly for 6 weeks to allow spontaneous pregnancy at the beginning of second menstrual cycle AMH FSH AFC will be reassessed
3months after the PRP injection all women considered poor responders 2groupswill undergo assisted reproductive therapy with antagonist protocol followed by a dose of 450 units of FSH Gonal F CinnaGen Iran Six days after gonadotropin therapy vaginal ultrasound will be performed to measure follicle diameter Once the follicular size is 12 mm the GnRH antagonist Cetrorelix Merck-Serono Germany will begin and gonadotropin continued When at least two dominant follicles reach the diameter of 18 mm on ultrasound ovulation will be stimulated using 10000 units of HCG and oocyte retrieval will be performed under general anesthesia 34 to 36 h after the HCG injection and the two groups will be compared in terms of the outcomes such as duration of stimulation dosage of gonadotrophine serum of estradiol level on the triggering day number and quality of oocytes and embryons and clinical pregnancy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None